Proven Results in Pediatric Patients1

Actor portrayals

High diagnostic accuracy of 18F-FET PET/MRI in pediatric CNS tumors1

Diagnostic accuracy results shown below reflect the subgroup analysis of previously treated lesions. Clinical impact results are shown separately and come from the overall study cohort.

Patient enrollment
64 previously treated subjects
(83 treated lesions)

Treated-lesion subgroup diagnostic performance

88%

Sensitivity

95% CI: 82, 94

100%

Specificity

95% CI: 82, 100

91%

Accuracy

95% CI: 87, 96

These results reflect the performance of combined 18F-FET PET/MRI in the subgroup of previously treated lesions.

54 of 54 tumoral lesions
were correctly identified as tumor

21 of 29 nontumor lesions
were correctly identified as nontumor

33%

Clinical impact in the overall study cohort1

In clinically challenging scans where MRI findings were inconclusive, adding 18F-FET PET changed the treatment plan in 10 of 30 scans (33%; 95% CI: 17, 53)

Analysis of previously treated lesions from a prospective pediatric CNS tumor study. Diagnostic accuracy was assessed at the lesion level for discrimination of tumor versus nontumor findings using combined 18F-FET PET/MRI, with pathology or clinical and radiologic follow-up as the reference standard. Clinical impact was assessed separately across the overall study cohort by a multidisciplinary team that first made a management decision using clinical information and MRI while blinded to PET, then reassessed the decision after 18F-FET PET results were revealed.

Imaging clarified treatment decisions in real patients who received Pixclara® PET.2,3

View Case Studies